TrialThe Lancet. Oncology2020

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Shaji K Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.